BPC 157 - Kalpa Pharmaceuticals

Research on BPC-157 was initiated in 1992 by Dr. Predrag Sikiric in Croatia, focusing on its healing capabilities. It was synthesized from a natural peptide found in gastric juice and showed potential in tissue repair models. Backing was initially provided by Pliva, a Croatian pharmaceutical firm, which discontinued support in 2005. Despite interest from Merck in acquiring rights, no transfer took place. BPC-157 later became available as a research compound, with Slovenian-based Diagen becoming its primary manufacturer.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about BPC 157 by Kalpa Pharmaceuticals, consult with your doctor or healthcare professional.